Musculoskeletal | Phase III Developments | UNITED STATES

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Pfizer to Host Free Webinar on Pfizer’s Advancement to Phase III Gene Therapy Clinical Trial

Lead Product(s): PF-06939926

Therapeutic Area: Musculoskeletal

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

First ever Phase III gene therapy clinical trial for Duchenne muscular dystrophy.

Ra Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology

Lead Product(s): Zilucoplan

Therapeutic Area: Musculoskeletal

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2020

Details:

the study demonstrated that zilucoplan resulted in rapid, clinically meaningful, statistically significant, and sustained improvements in the primary and key secondary endpoints.

Catabasis Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering

Lead Product(s): Edasalonexent

Therapeutic Area: Musculoskeletal

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Oppenheimer & Co.

Deal Size: $23.0 million Upfront Cash: Undisclosed

Deal Type: IPO January 30, 2020

Details:

Catabasis intends to use the net proceeds from the offering for clinical trial and other research and development activities; initial commercialization preparations; and for working capital.

Find

Find Musculoskeletal Drugs in Phase III Clinical Development in UNITED STATES

United States

A collaboration with SCORR Marketing

Product Type

Companies

Pfizer Inc

Pfizer to Host Free Webinar on Pfizer’s Advancement to Phase III Gene Therapy Clinical Trial

Ra Pharmaceuticals

Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology

Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering